When was Biohaven founded?

Biohaven was founded in 2022 and raised its 1st funding round 3 years after it was founded.

Where is Biohaven located?

Biohaven is headquartered in New Haven, United States.

How many employees does Biohaven have?

As of Sep 30, 2026, the latest employee count at Biohaven is 397.

Is Biohaven a funded company?

Biohaven is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Apr 28, 2025.

When was the latest funding round of Biohaven?

Biohaven's latest funding was a $***** Post IPO round on Apr 28, 2025, with participation from 1 investor.

Where does Biohaven rank among its competitors?

Biohaven ranks 596th amongst 4789 active competitors, of which 1073 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Biohaven?

Biohaven's top competitors include AbbVie, Jazz Pharmaceuticals and Gilead. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Biohaven - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of radiopharmaceuticals for the treatment of neurological and neuropsychiatric diseases. The company leverages its drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder, and spinocerebellar ataxia and myostatin inhibition for neuromuscular diseases.

Website: www.biohaven.com/
Social

Key Metrics

Founded Year

2022

Location

New Haven, United States

Stage

Public

Latest Funding Round

Post IPO, Apr 28, 2025, $*****

Investors

Oberland Capital & 1 more

Ranked

596^th among 4789 active competitors

Employee Count

397 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 596 more

Exit Details

Public

View Biohaven's full profile

Biohaven is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
BIOHAVEN LTD. CIN: 1935979 , United States, Active		-	-	-
BIOHAVEN PHARMACEUTICAL HOLDING CO LTD. CIN: 1689813 , United States, Active		$100M - $500M (As on Dec 31, 2021)	-	-

Biohaven got listed on May 04, 2017.

Click here to take a look at Biohaven's IPO in detail

Biohaven has raised funding over 1 round. Its latest funding round was a Post IPO round on Apr 28, 2025 for $*****. 1 investor participated in its latest round. Biohaven has 2 institutional investors.

Here is the list of recent funding rounds of Biohaven:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 28, 2025	1649549	Post IPO	5529272	9215345	9829928	1399506

Access funding benchmarks and valuations. Sign up today!

View details of Biohaven's funding rounds and investors

Biohaven's employee count trend

Biohaven has 397 employees as of Sep 26. Here is Biohaven's employee count trend over the years:

Uncover Biohaven's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biohaven include AbbVie, Jazz Pharmaceuticals and Gilead. Here is the list of Top 10 competitors of Biohaven, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 10 others	83/100
2nd	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal Ventures & 17 others	81/100
4th	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
5th	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
6th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
7th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
8th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
9th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
10th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
596th	Biohaven 2022, New Haven (United States), Public	Developer of radiopharmaceuticals for the treatment of neurological and neuropsychiatric diseases	-	Oberland Capital, Aperture Venture Partners	50/100